Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Nov;72(5):1245–1250. doi: 10.1038/bjc.1995.494

Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).

G Colucci 1, S Romito 1, V Gebbia 1, G Pacilio 1, F Giotta 1, A Testa 1, G Pezzella 1, E Durini 1, B Agostara 1, S Cariello 1, et al.
PMCID: PMC2033921  PMID: 7577476

Abstract

Sixty-four consecutive patients with locally advanced (n = 7) or metastatic breast cancer (n = 57), were treated with a combination of laevofolinic acid 100 mg m-2 plus 5-fluorouracil 340 mg m-2 i.v. on days 1-3, cyclophosphamide 600 mg m-2 i.v. on day 1 and epirubicin 90 mg m-2 i.v. on day 1. Epirubicin dose was progressively escalated by 10 mg m-2 per cycle up to 120 mg m-2 in the absence of dose-limiting toxicities. Granulocyte colony-stimulating factor (G-CSF) was given subcutaneously in order to prevent neutropenia. Epirubicin dosage could be increased to 100 mg m-2 in 53 patients (87%), to 110 mg m-2 in 31 patients (51%) and to 120 mg m-2 in 18 cases (30%). In most patients the dose-limiting toxicity was represented by myelosuppression. A statistically significant correlation was found between median white blood count (WBC) or absolute neutrophil count (ANC) nadir and epirubicin dose level (P = 0.009; P = 0.008). Moreover, a statistically significant correlation was observed between the number of chemotherapeutic cycles, nadir ANC and WBC and the occurrence of anaemia and thrombocytopenia of increasing severity. These data suggest the occurrence of progressive cumulative bone marrow toxicity. Although patients who reached different epirubicin levels showed differences in mean dose intensity, such differences were not statistically significant. No correlation was found between the increase in dose intensity and type, rate or duration of objective responses. In patients with metastatic breast cancer the overall response rate was 72% (95% CL 66-78%) with a 25% complete response rate. Median duration of response was 10 and 13 months respectively for complete and partial responses. All patients with locally advanced breast cancer had an objective response and underwent radical mastectomy. Projected median survival of the whole series of patients with metastatic breast cancer was 20 + months. These data demonstrate that the combination of 5-fluorouracil with laevofolinic acid, cyclophosphamide and epirubicin is very active against metastatic breast cancer. Use of G-CSF allows epirubicin dosage to be increased up to 120 mg m-2 cycle-1, but its use may be linked to the occurrence of sometimes severe cumulative haematological toxicity.

Full text

PDF
1245

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra C. J. Biochemical modulation: a modality that has come of therapeutic age. J Clin Oncol. 1991 Oct;9(10):1723–1726. doi: 10.1200/JCO.1991.9.10.1723. [DOI] [PubMed] [Google Scholar]
  2. Bonadonna G., Gianni L., Santoro A., Bonfante V., Bidoli P., Casali P., Demicheli R., Valagussa P. Drugs ten years later: epirubicin. Ann Oncol. 1993 May;4(5):359–369. doi: 10.1093/oxfordjournals.annonc.a058514. [DOI] [PubMed] [Google Scholar]
  3. Bronchud M. H., Howell A., Crowther D., Hopwood P., Souza L., Dexter T. M. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 1989 Jul;60(1):121–125. doi: 10.1038/bjc.1989.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cortes E. P., Holland J. F., Glidewell O. Amputation and adriamycin in primary osteosarcoma: a 5-year report. Cancer Treat Rep. 1978 Feb;62(2):271–277. [PubMed] [Google Scholar]
  5. Ferguson J. E., Dodwell D. J., Seymour A. M., Richards M. A., Howell A. High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. Br J Cancer. 1993 Apr;67(4):825–829. doi: 10.1038/bjc.1993.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6. [DOI] [PubMed] [Google Scholar]
  7. Gebbia V., Testa A., Valenza R., Borsellino N., Cipolla C., Cannata G., Curto G., Latteri M., Florena M., Gebbia N. A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother. 1993 Jun;5(3):186–190. doi: 10.1080/1120009x.1993.11739231. [DOI] [PubMed] [Google Scholar]
  8. Gebbia V., Testa A., Valenza R., Cipolla C., Amato C., Latteri M., Gebbia N., Florena M. Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma. Anticancer Res. 1993 Jan-Feb;13(1):141–144. [PubMed] [Google Scholar]
  9. Gebbia V., Valenza R., Testa A., Cannata G., Verderame F., Gebbia N. Escalating doses of mitoxantrone with granulocyte colony-stimulating factor (G-CSF) rescue plus 5-fluorouracil and high-dose levofolinic acid in metastatic breast cancer. Eur J Cancer. 1994;30A(11):1734–1736. doi: 10.1016/0959-8049(94)90609-2. [DOI] [PubMed] [Google Scholar]
  10. Habeshaw T., Paul J., Jones R., Stallard S., Stewart M., Kaye S. B., Soukop M., Symonds R. P., Reed N. S., Rankin E. M. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol. 1991 Feb;9(2):295–304. doi: 10.1200/JCO.1991.9.2.295. [DOI] [PubMed] [Google Scholar]
  11. Henderson I. C., Hayes D. F., Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol. 1988 Sep;6(9):1501–1515. doi: 10.1200/JCO.1988.6.9.1501. [DOI] [PubMed] [Google Scholar]
  12. Hoekman K., Wagstaff J., van Groeningen C. J., Vermorken J. B., Boven E., Pinedo H. M. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst. 1991 Nov 6;83(21):1546–1553. doi: 10.1093/jnci/83.21.1546. [DOI] [PubMed] [Google Scholar]
  13. Hryniuk W. M. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol. 1987 Mar;14(1):65–74. [PubMed] [Google Scholar]
  14. Loprinzi C. L. 5-Fluorouracil with leucovorin in breast cancer. Cancer. 1989 Mar 15;63(6 Suppl):1045–1047. doi: 10.1002/1097-0142(19890315)63:6+<1045::aid-cncr2820631310>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  15. Marschner N., Kreienberg R., Souchon R., Räth U., Eggeling B., Voigtmann R., Ruffert K., Schütte M., Ammon A., Kesztyüs T. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial. Semin Oncol. 1994 Feb;21(1 Suppl 1):10–16. [PubMed] [Google Scholar]
  16. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  17. Parnes H. L., Abrams J. S., Tait N., Minford J., Allen S. L., Duggan D., Aisner J. Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma. J Natl Cancer Inst. 1991 Jul 17;83(14):1017–1020. doi: 10.1093/jnci/83.14.1017. [DOI] [PubMed] [Google Scholar]
  18. Razek A., Valeriote F., Vietti T. Survival of hematopoietic and leukemic colony-forming cells in vivo following the administration of daunorubicin or adriamycin. Cancer Res. 1972 Jul;32(7):1496–1500. [PubMed] [Google Scholar]
  19. Tannock I. F., Boyd N. F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D., Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. doi: 10.1200/JCO.1988.6.9.1377. [DOI] [PubMed] [Google Scholar]
  20. Yates J., Glidewell O., Wiernik P., Cooper M. R., Steinberg D., Dosik H., Levy R., Hoagland C., Henry P., Gottlieb A. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982 Aug;60(2):454–462. [PubMed] [Google Scholar]
  21. Zaniboni A., Simoncini E., Marpicati P., Montini E., Ferrari V., Ferragni A., Boari L., Marini G. Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: preliminary results. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1151–1155. doi: 10.1016/0277-5379(89)90408-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES